Treats recurrent episodes. ANDA 201022, held by Macleods Pharms Ltd. Famciclovir.
As of Nov 16, 2026, ANDA 201022 (Famciclovir), held by Macleods Pharms Ltd, was first approved by FDA on Jan 12, 2012, with 6 approved supplements and 0 published complete response letters.
Famciclovir, USP a prodrug of penciclovir, is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 12, 2012 | Original application | Approved | None posted |
| Famciclovir125MG · tablet;oral | Famciclovir | Rx |
| Famciclovir250MG · tablet;oral | Famciclovir | Rx |
| Famciclovir500MG · tablet;oral | Famciclovir | Rx |
| Jun 7, 2023 | Supplement 33Labeling · Standard review | Approved | None posted |
| Jul 25, 2019 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jul 25, 2019 | Supplement 22Labeling · Standard review | Approved | None posted |
| Nov 19, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 30, 2013 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 30, 2013 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 12, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters